Search

Your search keyword '"Goren, Idan"' showing total 258 results

Search Constraints

Start Over You searched for: Author "Goren, Idan" Remove constraint Author: "Goren, Idan"
258 results on '"Goren, Idan"'

Search Results

2. Stricturing Crohn’s Disease Single-Cell RNA Sequencing Reveals Fibroblast Heterogeneity and Intercellular Interactions

3. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

5. Muscular hyperplasia in Crohn's disease strictures: through thick and thin.

6. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

7. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel

8. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial

10. Early Indolent Course of Crohn’s Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable

12. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.

13. Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis.

15. Pouch Care

16. Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis

17. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa

19. A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes

21. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

22. Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study

25. Autoimmune pancreatitis in patients with inflammatory bowel disease - a real-world multicentre collaborative ECCO CONFER study

27. Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN

28. 5‐aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease—A nationwide cohort study

32. Newly Diagnosed Crohn’s Disease Patients in India and Israel Display Distinct Presentations and Serological Markers: Insights from Prospective Cohorts

33. TRIM7/RNF90 promotes autophagy via regulation of ATG7 ubiquitination during L. monocytogenes infection.

34. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

35. Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series

37. Mo1586: A MICROBIOTA TARGETED, MEDITERRANEAN DIET-BASED NUTRITIONAL EDUCATION PROGRAM POSITIVELY MODIFIES THE INTESTINAL ECOSYSTEM OF HEALTHY INDIVIDUALS

38. Sa1630: PATIENT AND PHYSICIAN PERSPECTIVE ON DISEASE CONTROL 1-YEAR AFTER DIAGNOSIS OF CROHN'S DISEASE: RESULTS FROM REAL-WORLD PROSPECTIVE INCEPTION COHORT

39. Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES

40. Sa1601: FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

41. Mo1557: DRUG PERSISTENCE AND ENDOSCOPIC, HISTOLOGIC AND BIOCHEMICAL REMISSION RATES AMONG PATIENTS FOLLOWING ILEAL-ANAL POUCH ANASTOMOSIS TREATED WITH BIOLOGIC THERAPY: RESULTS FROM A PROSPECTIVE PATIENT COHORT

43. Mental Health, Work Presenteeism, and Exercise in Inflammatory Bowel Disease

44. TRIM7/RNF90 promotes autophagy via regulation of ATG7 ubiquitination during L. monocytogenes infection

45. sj-docx-1-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

46. sj-docx-2-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

47. 1142 INTEGRIN INHIBITION REDUCES PROFIBROTIC RESPONSES IN CROHN'S DISEASE (CD) HUMAN INTESTINAL MYOFIBROBLASTS IN VITRO AND AMELIORATES EXPERIMENTAL INTESTINAL FIBROSIS IN VIVO - A POTENTIAL NOVEL APPROACH TO CD STRICTURE THERAPY

48. COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience

49. An Inception Cohort of Patients with Newly Diagnosed Crohn's Disease: Therapeutic Targets Achieved One Year after Diagnosis

50. Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Catalog

Books, media, physical & digital resources